Top Pharmaceutical Companies in Montreal (22)
JAMP Pharma Group is a private Canadian company founded in 1988, originally a contract manufacturing organization. It is a leading generic player in the Canadian pharmaceutical industry, providing high-quality, affordable medicines and health solutions.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 52nd among Canada’s top 100 Research and Development (R&D) investors in 2023, with $40-50...
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on...
Alphanumeric is leading life science and healthcare organizations toward a more efficient future - where patients and providers are met with personalized communication at every stage of their journey. Our teams are driven to improve and enhance interpersonal and patient experiences across industries. We provide more than call centers - we go beyond them to provide top-tier customer service, patient...
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Lundbeck's Top Stability & Growth Strengths
Strong Revenue Growth: Feedback suggests total revenue increased at constant exchange rates across 2025 and into H1 2026, with double-digit gains in the U.S. and Europe supporting momentum.
Profitability: Earnings are considered to have scaled alongside revenue, with adjusted EBITDA rising materially, indicating improved profit leverage.
Product Line Growth: Strategic brands such as Vyepti and Rexulti are often cited as the primary engines of expansion, showing strong double-digit growth and contributing the majority of total revenue.
Sygnature Discovery creates exceptional scientific outcomes. For their customers, who bring life-changing medicines to patients; and for their people, who help make this possible. They are 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, they offer total confidentiality and commitment. Over the past 20 years, they’ve earned a track...
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes across oncology, neurology and cardiology. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
Lantheus's Top Stability & Growth Strengths
Strong Market Position & Advantage: PYLARIFY is described as the leading PSMA PET agent in the U.S., and DEFINITY is the most utilized ultrasound contrast agent, underscoring category leadership. Management’s 2026 plan emphasizes sustaining PSMA PET leadership and leveraging a broad manufacturing and distribution network.
Diversified Revenue Streams: Portfolio expansion into Alzheimer’s PET via NEURACEQ adds a second commercial PET pillar alongside PSMA and echocardiography contrast. Recent acquisitions and the SPECT divestiture concentrate the company around multiple higher‑growth PET diagnostics.
Future-Ready Strategy: FDA clearance of PYLARIFY TruVu with a phased 4Q26 launch is framed to expand capacity and strengthen supply. Management points to late‑stage catalysts and execution in 2026 as enablers of growth reacceleration from 2027.
Caprion Biosciences was a leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry, specializing in advanced immunology and proteomics services. It has since rebranded to CellCarta, a global contract research organization.
Circle K is a global convenience-store and fuel-retail company operating across multiple countries. Its locations provide gasoline and other energy products alongside prepared food, beverages, car-wash services, and electric-vehicle fast charging. In Denmark, Circle K operates both Circle K and INGO brands, serving customers on the move through a broad network of stations and emphasizing convenient food and drink for...
Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : A pharmaceutical group with a strong positioning : medical and natural The second largest dermo-cosmetics laboratory in the world The second largest private French pharmaceutical group The market leader...
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and...
Sandoz's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sandoz is widely characterized as a global leader in biosimilars and a top‑tier generics player, with multiple first‑to‑market and leading‑share launches (e.g., ustekinumab, denosumab) that reinforce competitive strength. Partnerships and European scale further underpin its standing across high‑value biologic categories.
Strong Revenue Growth: Reported net sales increased in 2024 and 2025, with biosimilars contributing strongly and rising as a share of sales. Guidance for 2026 indicates mid‑ to high‑single‑digit growth at constant currency, signaling continued top‑line momentum.
Profitability: Core EBITDA margins expanded in 2024 and 2025 alongside improvements in management free cash flow and ROIC. Guidance points to additional margin expansion in 2026 supported by a higher biosimilar mix and operational initiatives.
At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities...
Endo's Top Stability & Growth Strengths
Strong Market Position & Advantage: Xiaflex is the only FDA‑approved nonsurgical therapy for Peyronie’s disease and an FDA‑approved option for Dupuytren’s contracture, giving the franchise clear category leadership within this narrow segment. Marketing continued into 2025 with national campaigns reinforcing this positioning.
Product Line Growth: Xiaflex posted record 2024 sales and grew again in Q1 2025, with the Branded segment up in the quarter. New sterile injectable launches (e.g., ADRENALIN ready‑to‑use premixed bags) add to near‑term product momentum.
Future-Ready Strategy: The April 2024 emergence from Chapter 11 reduced debt and removed significant litigation overhang, enabling renewed focus on branded growth and selected sterile injectables. Management reaffirmed 2025 guidance implying stabilization with potential slight growth and announced portfolio‑reshaping moves including a combination with Mallinckrodt and an international divestiture.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global...
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital),...
Perceiv is a precision medicine company unlocking the potential of medical data and deep learning to optimize diagnosis and prognosis. Our mission is to improve the effectivenes of treatment by identifying the right patients that will benefit from a particular treatment. Our platform is used in situations in which precise decisions are required over heterogeneous populations such as precision medicine...
JAMP Pharma Group is a privately owned Canadian pharmaceutical company launched in 1988. Originally a contract manufacturing organization, it now provides high-quality medicines and healthcare solutions for patients and consumers. Its vertically integrated operations cover commercial activities, warehousing, quality assurance, controlled-substance storage, and cold-chain capabilities. The company supplies pharmacies and supports healthcare professionals and partners across Canada, with a focus...
The multinational Duchesnay with its affiliated companies is headquartered in Blainville, Quebec. The group consists of five pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad: - Duchesnay (Canada) and Duchesnay USA, both dedicated to women’s health; - Médunik Canada and Medunik USA, which provide treatments for rare diseases; and - Analog Pharma, an American generic drugs company,...
Aplantex has been created by a team of entrepreneurs and scientific specialists after a careful validation of the technical concept first formulated in 2019. With the support of our academic and industrial partners, we are now aiming at producing a large catalog of high value plant-based active ingredients to be used within the pharmaceutical, cosmetics and agri-food markets. Our proprietary...
